Business
Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025. Key Highlights Strong revenue growth with 9.2% reported growth (12.9% at CER1) to reach €952.2 million, ahead of guidance and supported by all regions
About this update from Fagron Sa
[{"type":"image","alt":"Fagron NV","displaySize":"","headline":null,"caption":"Fagron NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/01507f83c8cd7cebb0a99a82c723a556"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TBfMLlZobaCODCfSBVX7eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/01507f83c8cd7cebb0a99a82c723a556","width":300,"height":108}},"lazy":false},{"type":"text","content":"Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 February 2026 – 7AM CET","length":96,"tagName":"p"},{"type":"text","content":"Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA ","length":110,"tagName":"p"},{"type":"text","content":"Fagron, the leading global player in pharmaceutical compounding, today publishes its full year results for the period ending 31 December 2025.","length":142,"tagName":"p"},{"type":"text","content":"Key Highlights","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strong revenue growth with 9.2% reported growth (12.9% at CER1) to reach €952.2 million, ahead of guidance and supported by all regions and segments","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Organic growth at CER of 9.1% reflecting continued underlying demand and disciplined commercial execution ","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"Profitability increased with REBITDA up 10.9% YoY to €192.9 million, and REBITDA margin of 20.3%, supported by operating leverage and operational excellence initiatives","length":168,"tagName":"p"}]},{"val":[{"type":"text","content":"Solid cash generation with operating cash flow of €155.3 million, and free cash flow of €125.9 million2 (+29.0% YoY) ","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Leverage ratio decreased to 1.2x (2024: 1.4x), offering ample headroom to fund our expansion capex projects and signed acquisitions ","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued M&A momentum with 12 acquisitions announced across all regions and segments this year; integration of closed acquisitions progressing as planned","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"EPS of €1.25 (+13.6...